Overview

Cleveland BioLabs, Inc. (NASDAQ: CBLI)

Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development.

Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients.

Presently, we have nine product candidates in our pipeline that are being developed directly by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc.

Upcoming and Recent Events

Jun 14, 2013 at 10:00 AM
Cleveland BioLabs 2013 Annual Meeting

May 30, 2013
Cleveland BioLabs presentation at Second Annual Marcum Microcap Conference

View all »   Recent Releases

May 22, 2013
Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference

May 14, 2013
Cleveland BioLabs and Incuron Announce US and European Patent Allowances for Curaxins

Annual Report

2012 Annual Report

Investor Relations

Rachel Levine
Vice President, Investor Relations
Cleveland BioLabs, Inc.
Phone: +1 (646) 284-9439
Fax: +1 (716) 849-6820
E-mail: rlevine@cbiolabs.com

Management Team

Yakov Kogan, Ph.D., MBA
Chief Executive Officer

Michael Fonstein, Ph.D.
President

Andrei Gudkov, Ph.D., D. Sci.
Chief Scientific Officer

C. Neil Lyons, CPA
Chief Financial Officer

Jean Viallet, M.D.
Chief Development Officer

Ann Hards, Ph.D.
Executive Vice President, Regulatory Affairs and Quality Assurance

Michelle Ross, DVM, MS, Ph.D.
Senior Vice President, Public Health and Government Affairs

Debra Bowes, M.T.
Vice President, Business Development

Leah Brownlee, J.D.
Vice President, Compliance and Operations/Corporate Secretary

Anna Muchnik, MS
Vice President, Product Development

Andrei Purmal, Ph.D.
Vice President, Chemistry

Transfer Agent

Continental Stock Transfer & Trust Company.
17 Battery Place
8th Floor
New York, NY 10004
Tel: (212) 509-4000
Fax: (212) 509-5150

Auditors

Meaden & Moore, Ltd.